Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Updated: Acelyrin’s stock drops due to mixed Phase 2 data in thyroid eye disease
5 months ago
R&D
Teoxane issues competing buyout bid for Revance and its Botox rival
5 months ago
Deals
FDA offers suite of new guidance on AI, accelerated approvals, clinical trials and more
5 months ago
FDA+
'Microprotein' biotech Velia, backed by TCG and Foresite, to wind down
5 months ago
People
Startups
Anthem Biosciences eyes $397M public offering in India
5 months ago
Financing
Manufacturing
WuXi Biologics to sell Irish vaccine site to Merck for $500M
5 months ago
China
Manufacturing
Exclusive: Joe Jimenez's Aditum Bio rings in new year with $428M third fund
5 months ago
Financing
Startups
I-Mab stops work on CD73; Citius to pursue ‘strategic’ options
5 months ago
News Briefing
Every FDA drug approval from 2024: Fewer nods, but long-awaited treatments cross the finish line
5 months ago
Pharma
FDA+
Oculis’ eye drug clears Phase 2 in France as US development beckons
5 months ago
R&D
Exclusive: AI biotech Iambic snags CFO who helped steer Recursion-Exscientia deal
5 months ago
People
Startups
European macrocycle startup Orbis raises €90M
5 months ago
Financing
Neumora fails Ph3 depression study; Our review of 2024 megarounds; Pfizer cuts Sangamo pact; and more
5 months ago
Weekly
Florida car dealer joins insulin pricing fight against Eli Lilly, Sanofi
5 months ago
Pharma
FDA+
Eli Lilly seeks to join lawsuit over end of tirzepatide shortage
5 months ago
Pharma
Law
Novo petitions FDA over Victoza compounding as first generic wins approval
5 months ago
Pharma
FDA+
GSK’s Nucala bags another China approval, but biggest test yet to come
5 months ago
R&D
Pharma
After CagriSema, eyes are on Lilly’s oral GLP-1 as next key obesity play
5 months ago
R&D
Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts
5 months ago
Pharma
Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval
5 months ago
FDA+
FDA adcomm to review Novartis' Fabhalta in ultra-rare kidney disease
5 months ago
R&D
FDA+
Regeneron buys London-based ocular biotech
5 months ago
Startups
Deals
Hutchmed’s divestiture; Xgene reports Phase 2b win for non-opioid pain drug
5 months ago
News Briefing
A look at biotech's year of the megaround
5 months ago
Financing
Startups
First page
Previous page
59
60
61
62
63
64
65
Next page
Last page
